Is Apremilast (Otelor) a biological agent and its pharmacological properties

Apremilast is an oral, small-molecule phosphodiesterase (PDE4) inhibitor indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. It inhibits PDE4 activity and regulates intracellular cyclic adenosine monophosphate (cAMP) levels, thereby indirectly regulating inflammatory factors such as The expression of TNF-α, IL-17 and IL-23 achieves the effect of reducing inflammatory reactions and improving skin and joint symptoms. Because it is a chemically synthesized small molecule drug rather than produced by living cells or recombinant proteins, apremilast is not a biological agent but an oral small molecule targeted immunomodulatory drug.

The pharmacological properties of apremilast are mainly reflected in the selective regulation of inflammatory signaling pathways. By inhibiting PDE4, the intracellular cAMP level increases and activates protein kinase A (PKA) pathway, thereby inhibiting the expression of pro-inflammatory cytokines and promoting the secretion of anti-inflammatory factors such as IL-10. This two-way regulatory effect allows apremilast to reduce skin and joint inflammation while reducing the risk of systemic immunosuppression. It is safer and better tolerated than traditional glucocorticoids or broad-spectrum immunosuppressants.

In clinical applications, apremilast's oral administration and small molecule characteristics make it highly convenient. Unlike biological agents that require injection or intravenous infusion, patients can take them at home according to doctor's instructions without being limited by the number of infusions. At the same time, the drug is metabolized quickly, and adverse reactions can be quickly subsided by discontinuing the drug. Its metabolism is mainly carried out through the CYP3A4 pathway of the liver. Drug-drug interactions are relatively controllable, but it is still necessary to pay attention to dosage adjustments when used with potent CYP3A4 inhibitors or inducers.

In general, apremilast, as an oral small molecule PDE4 inhibitor, achieves precise intervention in psoriasis and psoriatic arthritis by regulating the cAMP mediated inflammatory signaling pathway. It is not a biological agent, but it is similar to some biological agents in terms of pharmacological mechanism, efficacy and safety, and can effectively control the inflammatory response. Due to oral convenience, controllability and good tolerance, apremilast has obvious advantages in long-term treatment and maintaining patients' quality of life.

Reference materials:https://www.drugs.com/